Clin2
NCT06024746Possibly a fitRecruiting

Finerenone plus SGLT2i for hospitalized heart failure

Heart Failure

Treatments studied

Part of Heart & circulation clinical trials.

This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
1,500 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You are currently in the hospital or were recently discharged for heart failure.
  • You had heart failure symptoms when you were admitted.
  • You received at least one IV water pill (diuretic) during this hospital stay.
  • Your BNP or NT-proBNP levels are high (a heart stress test).
  • You are not already taking finerenone or an SGLT2i medicine.
  • Your kidneys are working well (eGFR above 30) and potassium level is normal (below 5.0).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07351864Not yet recruiting· Phase 4
Finerenone plus SGLT2 inhibitors for heart failure

This trial tests two medications (finerenone and SGLT2 inhibitors) together in heart failure. It aims to see if the combination works better than either alone.

Al Mansurah
NCT06008197Recruiting· Phase 3
A study of finerenone for hospitalized heart failure patients

This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.

Birmingham, Alabama
NCT07442448Enrolling by invitation· Phase 4
Study of Finerenone for heart and kidney health in diabetes

This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.

Taipei
NCT07583173Not yet recruiting· Phase 4
Finerenone for heart failure with preserved ejection fraction

This study tests whether a medication called finerenone can reduce scarring in the heart and improve heart function in people with heart failure who have ejection fractions of 40% or higher. You may be eligible if you've recently had heart failure symptoms requiring emergency care or medication changes.

Beijing
NCT07270367Not yet recruiting· Phase 3
Finerenone study for heart thickening

This trial tests if a medication called finerenone can improve heart structure and function in people whose heart walls are thickened. It may help people with early heart failure or related conditions like diabetes or kidney disease.

Cambridge, Ontario
NCT07273838Recruiting· Phase 2
SGLT2 inhibitor for acute heart and kidney failure

This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.

New Haven, Connecticut

Hear when a new Heart failure trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.